Taysha Gene Therapies Inc. (TSHA) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Taysha Gene Therapies Inc... (TSHA)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

1.63

0.01 (0.62%)

At close: Jan 15, 2025, 2:27 PM

undefined% (undefined)

Bid	1.63
Market Cap	334.06M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	0.63
PE Ratio (ttm)	2.59
Forward PE	n/a
Analyst	Buy

Ask	1.64
Volume	1,158,467
Avg. Volume (20D)	4,494,106
Open	1.70
Previous Close	1.62
Day's Range	1.60 - 1.74
52-Week Range	1.19 - 4.32
Beta	undefined

About TSHA

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of ...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Sep 24, 2020

Employees 52

Stock Exchange NASDAQ

Ticker Symbol TSHA

Website https://www.tayshagtx.com

Analyst Forecast

According to 8 analyst ratings, the average rating for TSHA stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 329.45% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

2 months ago · Source

+2.71%

Taysha Gene Therapies shares are trading higher. C... Unlock content with Pro Subscription

2 months ago · Source

+46.63%

Taysha Gene Therapies shares are trading higher. Needham reiterated a Buy rating on the stock and Cantor Fitzgerald reiterated an Overweight rating.

News

2 months ago · benzinga.com

Advance Auto Parts Posts Weak Results, Joins Harrow, Taysha Gene Therapies And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

U.S. stock futures were higher this morning, with the Dow futures gaining more than 50 points on Thursday.

2 months ago · seekingalpha.com

Taysha Gene Therapies, Inc. (TSHA) Q3 2024 Earnings Call Transcript

Taysha Gene Therapies, Inc. (NASDAQ:TSHA ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Hayleigh Collins - Director and Head, Investor Relations Sean Nolan - Chie...

2 months ago · zacks.com

Taysha Gene Therapies, Inc. (TSHA) Reports Q3 Loss, Lags Revenue Estimates

Taysha Gene Therapies, Inc. (TSHA) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.13 per share a year ago.